{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:07:36Z","timestamp":1740136056326,"version":"3.37.3"},"reference-count":97,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T00:00:00Z","timestamp":1633219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Gonadotropins can be administered every 5 days under intradermal injection in in vitro fertilization (IVF) treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the effectiveness of intradermal injection of recombinant human FSH (rhFSH) for women undergoing IVF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Women who received their first IVF treatment enrolled in this prospective intervention in 2018. All women received a bolus of 900 IU rhFSH intradermally at day 2 of the treatment cycle followed by additional dosage of rhFSH at day 7 and\/or day 10. The main outcome measures included the total dose of rhFSH and number of injections required, sequential serum FSH level detected, and number of mature oocytes retrieved.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy women completed the study. On average, 2.31\u2005\u00b1\u20050.73 injections and 1662\u2005\u00b1\u2005397 IU of rhFSH were administered. While the baseline FSH level was 5.6\u2005\u00b1\u20052.2 IU\/L, the serum concentrations of FSH after rhFSH administration were 35.3\u2005\u00b1\u20057.0 on the first day (24 hours) and 10.7\u2005\u00b1\u20053.7 IU\/L on the fifth day (120 hours). A total of 10.5\u2005\u00b1\u20056.6 mature oocytes were retrieved, resulting in 7.3\u2005\u00b1\u20055.1 pronuclear embryos; 1.8\u2005\u00b1\u20050.6 embryos were transferred to the uterus. Our findings resulted in 72% fertilization, 91% cleavage, 31% implantation, and 36% live birth rates. Although fewer larger follicles were found, noninferiority results were noted in the mature oocytes retrieved, good embryos available, and clinical pregnancy rate compared with those received conventional daily subcutaneous rhFSH administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Intradermal administration of rhFSH, with a smaller dose of rhFSH and fewer injections, may achieve the goal of a cost-effective and more patient-friendly regimen.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgab709","type":"journal-article","created":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T16:52:20Z","timestamp":1633279940000},"page":"e716-e733","source":"Crossref","is-referenced-by-count":3,"title":["Extended Injection Intervals of Gonadotropins by Intradermal Administration in IVF Treatment"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8082-1196","authenticated-orcid":false,"given":"Chao Chin","family":"Hsu","sequence":"first","affiliation":[{"name":"Taiwan United Birth-promoting Experts Fertility Clinic, Tainan, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, Tainan, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui Hua","family":"Chang","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Department of Pharmacy, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"},{"name":"Department of Pharmacy, National Cheng Kung University Hospital, Dou-Liou Branch, Yunlin,Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosie","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonam","family":"Dorjee","sequence":"additional","affiliation":[{"name":"Taiwan United Birth-promoting Experts Fertility Clinic, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2021,10,3]]},"reference":[{"key":"2022011806211796500_CIT0001","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fendo.2021.675670","article-title":"Optimising follicular development, pituitary suppression, triggering and luteal phase support during assisted reproductive technology: a Delphi consensus","volume":"12","author":"Orvieto","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2022011806211796500_CIT0002","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3389\/fendo.2019.00429","article-title":"The development of gonadotropins for clinical use in the treatment of infertility","volume":"10","author":"Lunenfeld","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2022011806211796500_CIT0003","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fmed.2019.00197","article-title":"New twists in ovarian stimulation and their practical implications","volume":"6","author":"Pirtea","year":"2019","journal-title":"Front Med (Lausanne)."},{"issue":"2","key":"2022011806211796500_CIT0004","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertil Steril."},{"issue":"1","key":"2022011806211796500_CIT0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humupd\/dmm034","article-title":"Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation","volume":"14","author":"Fauser","year":"2008","journal-title":"Hum Reprod Update."},{"issue":"2","key":"2022011806211796500_CIT0006","first-page":"370","article-title":"Conventional ovarian stimulation and single embryo transfer for IVF\/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?","volume":"31","author":"Drakopoulos","year":"2016","journal-title":"Hum Reprod."},{"issue":"5","key":"2022011806211796500_CIT0007","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.rbmo.2019.06.013","article-title":"Is there an association between oocyte number and embryo quality? A systematic review and meta-analysis","volume":"39","author":"Vermey","year":"2019","journal-title":"Reprod Biomed Online."},{"issue":"4","key":"2022011806211796500_CIT0008","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.fertnstert.2014.12.120","article-title":"Association of number of retrieved oocytes with live birth rate and birth weight: an analysis of 231,815 cycles of in vitro fertilization","volume":"103","author":"Baker","year":"2015","journal-title":"Fertil Steril."},{"issue":"4","key":"2022011806211796500_CIT0009","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1472-6483(10)60633-5","article-title":"Optimum number of oocytes for a successful first IVF treatment cycle","volume":"13","author":"van der Gaast","year":"2006","journal-title":"Reprod Biomed Online."},{"issue":"7","key":"2022011806211796500_CIT0010","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/humrep\/der106","article-title":"Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles","volume":"26","author":"Sunkara","year":"2011","journal-title":"Hum Reprod."},{"issue":"4","key":"2022011806211796500_CIT0011","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.fertnstert.2017.08.023","article-title":"Introduction: contemporary approaches to alternative ovarian stimulation strategies for in vitro fertilization","volume":"108","author":"Paulson","year":"2017","journal-title":"Fertil Steril."},{"issue":"1","key":"2022011806211796500_CIT0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1479-828X.1978.tb00011.x","article-title":"Pituitary control of ovarian function\u2013concepts derived from gonadotrophin therapy","volume":"18","author":"Brown","year":"1978","journal-title":"Aust N Z J Obstet Gynaecol."},{"issue":"1","key":"2022011806211796500_CIT0013","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0015-0282(16)57652-3","article-title":"Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle","volume":"64","author":"van Santbrink","year":"1995","journal-title":"Fertil Steril."},{"issue":"4","key":"2022011806211796500_CIT0014","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0015-0282(16)56644-8","article-title":"Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH","volume":"61","author":"le Cotonnec","year":"1994","journal-title":"Fertil Steril."},{"issue":"6","key":"2022011806211796500_CIT0015","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0015-0282(00)00542-2","article-title":"A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim*\/Puregon) in healthy female volunteers","volume":"73","author":"Voortman","year":"2000","journal-title":"Fertil Steril."},{"issue":"4","key":"2022011806211796500_CIT0016","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0015-0282(16)57467-6","article-title":"Pharmacokinetics of follicle-stimulating hormone: clinical significance","volume":"63","author":"Ben-Rafael","year":"1995","journal-title":"Fertil Steril."},{"issue":"1","key":"2022011806211796500_CIT0017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1472-6483(10)60498-1","article-title":"Unsuccessful oocyte retrieval: technical artefact or genuine \u2018empty follicle syndrome\u2019?","volume":"8","author":"Bustillo","year":"2004","journal-title":"Reprod Biomed Online."},{"key":"2022011806211796500_CIT0018","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2147\/TCRM.S64222","article-title":"Managing infertility with the follitropin alfa prefilled pen injector - patient considerations","volume":"11","author":"B\u00fchler","year":"2015","journal-title":"Ther Clin Risk Manag."},{"key":"2022011806211796500_CIT0019","article-title":"Devenir d\u2019un produit marque injecte par quatre voies differentes","volume":"62","author":"Kaplan","year":"1985","journal-title":"Bull SFM (la Societe Francaise de Mesotherapie)."},{"volume-title":"Trait\u00e9 de m\u00e9soth\u00e9rapie","author":"Coz","key":"2022011806211796500_CIT0020"},{"key":"2022011806211796500_CIT0021","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1477-7827-7-107","article-title":"The absorption and uptake of recombinant human follicle-stimulating hormone through vaginal subcutaneous injections - a pharmacokinetic study","volume":"7(1)","author":"Hsu","year":"2009","journal-title":"Reprod Biol Endocrinol."},{"issue":"6","key":"2022011806211796500_CIT0022","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.fertnstert.2010.12.007","article-title":"Abdominal mesotherapy injection extended the absorption of follicle-stimulating hormone","volume":"95","author":"Hsu","year":"2011","journal-title":"Fertil Steril."},{"key":"2022011806211796500_CIT0023","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.12688\/f1000research.10382.1","article-title":"The novel POSEIDON stratification of \u2018Low prognosis patients in Assisted Reproductive Technology\u2019 and its proposed marker of successful outcome","volume":"5","author":"Humaidan","year":"2016","journal-title":"F1000Res."},{"key":"2022011806211796500_CIT0024","first-page":"1","article-title":"What is mesotherapy? Recommendations from an international consensus","volume":"14","author":"Mammucari","year":"2014","journal-title":"Trends Med."},{"issue":"5","key":"2022011806211796500_CIT0025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1472-6483(10)60473-7","article-title":"Intermittent vaginal injections of gonadotrophins for ovarian stimulation in IVF treatment","volume":"16","author":"Hsu","year":"2008","journal-title":"Reprod Biomed Online."},{"key":"2022011806211796500_CIT0026","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1477-7827-9-112","article-title":"Ovarian sensitivity index is strongly related to circulating AMH and may be used to predict ovarian response to exogenous gonadotropins in IVF","volume":"9","author":"Biasoni","year":"2011","journal-title":"Reprod Biol Endocrinol."},{"issue":"4","key":"2022011806211796500_CIT0027","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/humrep\/der479","article-title":"Antral follicle responsiveness to follicle-stimulating hormone administration assessed by the Follicular Output RaTe (FORT) may predict in vitro fertilization-embryo transfer outcome","volume":"27","author":"Gallot","year":"2012","journal-title":"Hum Reprod."},{"key":"2022011806211796500_CIT0028","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3389\/fendo.2018.00589","article-title":"Understanding ovarian hypo-response to exogenous gonadotropin in ovarian stimulation and its new proposed marker-the follicle-to-oocyte (FOI) index","volume":"9","author":"Alviggi","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"author":"Chang","key":"2022011806211796500_CIT0029","article-title":"Supplementary Table 1. The correlation of serum FSH, E2 levels and the growth of ovarian follicles, as well as mature oocytes retrieved. Mendeley Data, V1. Deposited September 17, 2021."},{"issue":"8","key":"2022011806211796500_CIT0030","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","article-title":"The impact of reducing dose frequency on health outcomes","volume":"25","author":"Richter","year":"2003","journal-title":"Clin Ther."},{"issue":"1","key":"2022011806211796500_CIT0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/09513590.2015.1102879","article-title":"The use of ovarian reserve markers in IVF clinical practice: a national consensus","volume":"32","author":"La Marca","year":"2016","journal-title":"Gynecol Endocrinol."},{"issue":"2","key":"2022011806211796500_CIT0032","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/humupd\/dmaa035","article-title":"Mild versus conventional ovarian stimulation for IVF in poor, normal and hyper-responders: a systematic review and meta-analysis","volume":"27","author":"Datta","year":"2021","journal-title":"Hum Reprod Update."},{"issue":"2","key":"2022011806211796500_CIT0033","first-page":"83","article-title":"Ovarian sensitivity index (OSI): validating the use of a marker for ovarian responsiveness in IVF","volume":"20","author":"Yadav","year":"2019","journal-title":"J Reprod Infertil."},{"issue":"6","key":"2022011806211796500_CIT0034","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0015-0282(16)57610-9","article-title":"The follicle-stimulating hormone threshold level for follicle maturation in superovulated cycles","volume":"63","author":"Lolis","year":"1995","journal-title":"Fertil Steril."},{"issue":"4","key":"2022011806211796500_CIT0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.rbmo.2020.05.010","article-title":"Mild ovarian stimulation for IVF is the smartest way forward","volume":"41","author":"Nargund","year":"2020","journal-title":"Reprod Biomed Online."},{"key":"2022011806211796500_CIT0036","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.fertnstert.2020.02.082","article-title":"Higher total gonadotropin dose but not length of stimulation is independently associated with decreased live birth rate in fresh in vitro fertilization-embryo transfer (IVF-ET) cycles: analysis of 14,866 cycles from the SART registry","volume":"113","author":"Kappy","year":"2020","journal-title":"Fertil Steril."},{"issue":"12","key":"2022011806211796500_CIT0037","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/aogs.13032","article-title":"Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review","volume":"95","author":"van Tilborg","year":"2016","journal-title":"Acta Obstet Gynecol Scand."},{"issue":"6","key":"2022011806211796500_CIT0038","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.fertnstert.2007.05.055","article-title":"Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization","volume":"89","author":"Pal","year":"2008","journal-title":"Fertil Steril."},{"issue":"3","key":"2022011806211796500_CIT0039","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.fertnstert.2020.04.027","article-title":"Total follicle stimulating hormone dose is negatively correlated with live births in a donor\/recipient model with fresh transfer: an analysis of 8,627 cycles from the Society for Assisted Reproductive Technology Registry","volume":"114","author":"Shaia","year":"2020","journal-title":"Fertil Steril."},{"issue":"6","key":"2022011806211796500_CIT0040","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.fertnstert.2020.06.021","article-title":"Differential impact of controlled ovarian hyperstimulation on live birth rate in fresh versus frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome System study","volume":"114","author":"Gerber","year":"2020","journal-title":"Fertil Steril."},{"issue":"5","key":"2022011806211796500_CIT0041","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.fertnstert.2013.06.049","article-title":"Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem","volume":"100","author":"Huber","year":"2013","journal-title":"Fertil Steril."},{"issue":"4","key":"2022011806211796500_CIT0042","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.fertnstert.2013.12.026","article-title":"Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles","volume":"101","author":"Steward","year":"2014","journal-title":"Fertil Steril."},{"issue":"2","key":"2022011806211796500_CIT0043","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/humrep\/des389","article-title":"High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol","volume":"28","author":"Fatemi","year":"2013","journal-title":"Hum Reprod."},{"issue":"3","key":"2022011806211796500_CIT0044","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/09513590.2020.1770214","article-title":"How fixed versus variable gonadotropin dose during controlled ovarian stimulation could influence the management of infertility patients undergoing IVF treatment: a national Delphi consensus","volume":"37","author":"Bulletti","year":"2021","journal-title":"Gynecol Endocrinol."},{"key":"2022011806211796500_CIT0045","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fendo.2018.00193","article-title":"Follicle size on day of trigger most likely to yield a mature oocyte","volume":"9","author":"Abbara","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"4","key":"2022011806211796500_CIT0046","first-page":"1292","article-title":"The follicle-stimulating hormone (FSH) threshold\/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects follicle development","volume":"83","author":"Schipper","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022011806211796500_CIT0047","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0950-3552(05)80132-4","article-title":"The FSH threshold concept in clinical ovulation induction","volume":"7","author":"Schoemaker","year":"1993","journal-title":"Baillieres Clin Obstet Gynaecol."},{"issue":"3","key":"2022011806211796500_CIT0048","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.fertnstert.2004.01.043","article-title":"Estimation of the follicle-stimulating hormone (FSH) threshold for initiating the final stages of follicular development in women with elevated FSH levels in the early follicular phase","volume":"82","author":"de Koning","year":"2004","journal-title":"Fertil Steril."},{"key":"2022011806211796500_CIT0049","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fendo.2019.00579","article-title":"FSH requirements for follicle growth during controlled ovarian stimulation","volume":"10","author":"Abbara","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"2022011806211796500_CIT0050","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0015-0282(16)55624-6","article-title":"Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers","volume":"59","author":"Mannaerts","year":"1993","journal-title":"Fertil Steril."},{"issue":"2","key":"2022011806211796500_CIT0051","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/humupd\/2.2.153","article-title":"Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy","volume":"2","author":"Mannaerts","year":"1996","journal-title":"Hum Reprod Update."},{"issue":"7","key":"2022011806211796500_CIT0052","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/humrep\/14.7.1698","article-title":"Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon\u00ae) by Pen-injector and syringe","volume":"14","author":"Voortman","year":"1999","journal-title":"Hum Reprod."},{"volume-title":"Introduction to Pharmacokinetics and Pharmacodynamics: The Quantitative Basis of Drug Therapy.","year":"2006","author":"Tozer","key":"2022011806211796500_CIT0053"},{"issue":"2","key":"2022011806211796500_CIT0054","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1389200221666200401105119","article-title":"Has the time come to employ population and individual bioequivalence for the evaluation of generics?","volume":"21","author":"Micheal","year":"2020","journal-title":"Curr Drug Metab."},{"key":"2022011806211796500_CIT0055","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fendo.2019.00579","article-title":"FSH requirements for follicle growth during controlled ovarian stimulation","volume":"10","author":"Abbara","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"12","key":"2022011806211796500_CIT0056","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/humrep\/dex318","article-title":"Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 1: the predicted poor responder","volume":"32","author":"van Tilborg","year":"2017","journal-title":"Hum Reprod."},{"issue":"8","key":"2022011806211796500_CIT0057","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/humrep\/17.8.2016","article-title":"Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation","volume":"17","author":"Humaidan","year":"2002","journal-title":"Hum Reprod."},{"issue":"8","key":"2022011806211796500_CIT0058","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/oxfordjournals.humrep.a137223","article-title":"Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist\/HMG superovulation for in-vitro fertilization","volume":"5","author":"Smitz","year":"1990","journal-title":"Hum Reprod."},{"issue":"5","key":"2022011806211796500_CIT0059","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0015-0282(99)00090-4","article-title":"Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization","volume":"71","author":"Enskog","year":"1999","journal-title":"Fertil Steril."},{"issue":"10","key":"2022011806211796500_CIT0060","doi-asserted-by":"crossref","first-page":"e0140286","DOI":"10.1371\/journal.pone.0140286","article-title":"Is the GnRH antagonist protocol effective at preventing OHSS for potentially high responders undergoing IVF\/ICSI?","volume":"10","author":"Xing","year":"2015","journal-title":"PLoS One."},{"issue":"1","key":"2022011806211796500_CIT0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12958-021-00744-x","article-title":"Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017)","volume":"19","author":"Fatemi","year":"2021","journal-title":"Reprod Biol Endocrinol."},{"issue":"2","key":"2022011806211796500_CIT0062","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0015-0282(16)55188-7","article-title":"Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment","volume":"58","author":"Navot","year":"1992","journal-title":"Fertil Steril."},{"issue":"8","key":"2022011806211796500_CIT0063","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/humrep\/17.8.1987","article-title":"Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females","volume":"17","author":"Duijkers","year":"2002","journal-title":"Hum Reprod."},{"issue":"4","key":"2022011806211796500_CIT0064","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/11206890-000000000-00000","article-title":"Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction","volume":"25","author":"Croxtall","year":"2011","journal-title":"BioDrugs."},{"issue":"4","key":"2022011806211796500_CIT0065","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.rbmo.2017.06.025","article-title":"Importance of a 5- versus 7-day pill-free interval in a GnRH antagonist protocol using corifollitropin alfa: a prospective cohort study in oocyte donors","volume":"35","author":"P\u00e9rez-Calvo","year":"2017","journal-title":"Reprod Biomed Online."},{"issue":"4","key":"2022011806211796500_CIT0066","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.fertnstert.2012.01.092","article-title":"Is there a place for corifollitropin alfa in IVF\/ICSI cycles? A systematic review and meta-analysis","volume":"97","author":"Mahmoud Youssef","year":"2012","journal-title":"Fertil Steril."},{"key":"2022011806211796500_CIT0067","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13048-015-0160-4","article-title":"Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis","volume":"8(1)","author":"Fensore","year":"2015","journal-title":"J Ovarian Res."},{"issue":"5","key":"2022011806211796500_CIT0068","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1210\/jc.2003-031766","article-title":"Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization","volume":"89","author":"Devroey","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022011806211796500_CIT0069","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.rbmo.2017.03.004","article-title":"Follicular output rate can predict clinical pregnancy in women with unexplained infertility undergoing IVF\/ICSI: a prospective cohort study","volume":"34","author":"Hassan","year":"2017","journal-title":"Reprod Biomed Online."},{"key":"2022011806211796500_CIT0070","doi-asserted-by":"crossref","first-page":"436959","DOI":"10.1155\/2012\/436959","article-title":"Role of mesotherapy in musculoskeletal pain: opinions from the Italian Society of Mesotherapy","volume":"2012","author":"Mammucari","year":"2012","journal-title":"Evid Based Complement Alternat Med."},{"issue":"6","key":"2022011806211796500_CIT0071","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2230.1999.00537.x","article-title":"Visualization of dermal blood vessels\u2013capillaroscopy","volume":"24","author":"Hern","year":"1999","journal-title":"Clin Exp Dermatol."},{"issue":"2","key":"2022011806211796500_CIT0072","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/srt.12243","article-title":"Evaluation of mesotherapy as a transdermal drug delivery tool","volume":"22","author":"Kim","year":"2016","journal-title":"Skin Res Technol."},{"issue":"1-2","key":"2022011806211796500_CIT0073","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0378-5173(02)00084-4","article-title":"Estimation of intradermal disposition kinetics of drugs: II. Factors determining penetration of drugs from viable skin to muscular layer","volume":"239","author":"Higaki","year":"2002","journal-title":"Int J Pharm."},{"issue":"1","key":"2022011806211796500_CIT0074","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res."},{"issue":"1","key":"2022011806211796500_CIT0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin Immunopathol."},{"issue":"7","key":"2022011806211796500_CIT0076","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/0091270010378859","article-title":"Microneedles: a valuable physical enhancer to increase transdermal drug delivery","volume":"51","author":"Escobar-Ch\u00e1vez","year":"2011","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"2022011806211796500_CIT0077","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3390\/pharmaceutics12060569","article-title":"Microneedle-based delivery: an overview of current applications and trends","volume":"12","author":"Guillot","year":"2020","journal-title":"Pharmaceutics."},{"issue":"2","key":"2022011806211796500_CIT0078","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10544-012-9717-9","article-title":"Hollow microneedles for intradermal injection fabricated by sacrificial micromolding and selective electrodeposition","volume":"15","author":"Norman","year":"2013","journal-title":"Biomed Microdevices."},{"issue":"4","key":"2022011806211796500_CIT0079","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/dia.2010.0183","article-title":"Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes","volume":"13","author":"Pettis","year":"2011","journal-title":"Diabetes Technol Ther."},{"issue":"1","key":"2022011806211796500_CIT0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-32026-9","article-title":"Fluid absorption by skin tissue during intradermal injections through hollow microneedles","volume":"8","author":"Shrestha","year":"2018","journal-title":"Sci Rep."},{"issue":"1","key":"2022011806211796500_CIT0081","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem Biol Drug Des."},{"issue":"11","key":"2022011806211796500_CIT0082","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.4155\/tde.13.104","article-title":"Basics and recent advances in peptide and protein drug delivery","volume":"4","author":"Bruno","year":"2013","journal-title":"Ther Deliv."},{"issue":"1","key":"2022011806211796500_CIT0083","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1210\/edrv-11-1-177","article-title":"Molecular biology of the pituitary gonadotropins","volume":"11","author":"Gharib","year":"1990","journal-title":"Endocr Rev."},{"issue":"1","key":"2022011806211796500_CIT0084","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0021-9258(19)57352-5","article-title":"Asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin. II. Distributions of sulfated and sialylated oligosaccharides on bovine, ovine, and human pituitary glycoprotein hormones","volume":"263","author":"Green","year":"1988","journal-title":"J Biol Chem."},{"issue":"3","key":"2022011806211796500_CIT0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1385\/ENDO:11:3:205","article-title":"Role of glycosylation in function of follicle-stimulating hormone","volume":"11","author":"Ulloa-Aguirre","year":"1999","journal-title":"Endocrine."},{"key":"2022011806211796500_CIT0086","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fendo.2021.636038","article-title":"New human follitropin preparations: how glycan structural differences may affect biochemical and biological function and clinical effect","volume":"12","author":"Dias","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"2022011806211796500_CIT0087","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.xphs.2019.08.005","article-title":"Proteolysis and oxidation of therapeutic proteins after intradermal or subcutaneous administration","volume":"109","author":"Varkhede","year":"2020","journal-title":"J Pharm Sci."},{"issue":"7","key":"2022011806211796500_CIT0088","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1042\/BJ20151227","article-title":"Protein oxidation and peroxidation","volume":"473","author":"Davies","year":"2016","journal-title":"Biochem J."},{"issue":"12","key":"2022011806211796500_CIT0089","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00018-011-0682-x","article-title":"Highly reactive oxygen species: detection, formation, and possible functions","volume":"68","author":"Freinbichler","year":"2011","journal-title":"Cell Mol Life Sci."},{"issue":"1s","key":"2022011806211796500_CIT0090","doi-asserted-by":"crossref","first-page":"130s","DOI":"10.18433\/jpps30028","article-title":"Understanding the monoclonal antibody disposition after subcutaneous administration using a minimal physiologically based pharmacokinetic model","volume":"21","author":"Varkhede","year":"2018","journal-title":"J Pharm Pharm Sci."},{"issue":"1-2","key":"2022011806211796500_CIT0091","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0169-409X(01)00153-3","article-title":"Lymphatic transport of proteins after s.c. injection: implications of animal model selection","volume":"50","author":"Porter","year":"2001","journal-title":"Adv Drug Deliv Rev."},{"issue":"1","key":"2022011806211796500_CIT0092","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1530\/acta.0.1180154","article-title":"Subcutaneous degradation of biosynthetic human growth hormone in growth hormone deficient patients","volume":"118","author":"J\u00f8rgensen","year":"1988","journal-title":"Acta Endocrinol (Copenh)."},{"issue":"1","key":"2022011806211796500_CIT0093","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1248\/bpb1978.8.25","article-title":"Fate of porcine and human insulin at the subcutaneous injection site. I. degradation and absorption of insulins in the rat","volume":"8","author":"Okumura","year":"1985","journal-title":"J Pharmacobio-dynamics."},{"issue":"5","key":"2022011806211796500_CIT0094","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2265.1991.tb03557.x","article-title":"The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh","volume":"35","author":"Beshyah","year":"1991","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"2022011806211796500_CIT0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/diacare.5.2.77","article-title":"Absorption kinetics and biologic effects of subcutaneously injected insulin preparations","volume":"5","author":"Berger","year":"1982","journal-title":"Diabetes Care."},{"key":"2022011806211796500_CIT0096","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fendo.2020.00050","article-title":"Live birth in woman with premature ovarian insufficiency receiving ovarian administration of platelet-rich plasma (PRP) in combination with gonadotropin: a case report","volume":"11","author":"Hsu","year":"2020","journal-title":"Front Endocrinol."},{"issue":"6","key":"2022011806211796500_CIT0097","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/GME.0000000000001746","article-title":"Resumed ovarian function and pregnancy in early menopausal women by whole dimension subcortical ovarian administration of platelet-rich plasma and gonadotropins","volume":"28","author":"Hsu","year":"2021","journal-title":"Menopause."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab709\/40795574\/dgab709.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/2\/e716\/42224651\/dgab709.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/2\/e716\/42224651\/dgab709.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:28:30Z","timestamp":1673396910000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/2\/e716\/6380613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,3]]},"references-count":97,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,10,3]]},"published-print":{"date-parts":[[2022,1,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab709","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"type":"print","value":"0021-972X"},{"type":"electronic","value":"1945-7197"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,10,3]]}}}